Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Duboisdomein 30, 6229, GT, Maastricht, the Netherlands.
Cedars-Sinai, Los Angeles, CA, USA.
Arch Osteoporos. 2022 Apr 4;17(1):57. doi: 10.1007/s11657-022-01075-z.
US patients with osteoporosis included in three focus groups identified efficacy, safety, cost, and convenience as important attributes of treatment when choosing between anabolic therapies with high stated preference for the solid Microstructured Transdermal System.
The current study evaluated patient perspective and relative importance of treatment attributes of in-home daily self-administration of abaloparatide-solid Microstructured Transdermal System (sMTS) compared with other anabolic agents (i.e. in-home daily subcutaneous self-injections, and monthly subcutaneous injections at doctor office) among a group of US patients with osteoporosis.
The current study included systematic literature reviews, experts' consultation and three online patients focus groups (n=27), including patients ≥50 years of age at high risk for fracture. Nominal Group Technique was used by asking patients to (1) Individually identify characteristics that would be important for them when choosing between anabolic treatments, (2) Share ideas and discuss perspectives with other patients, (3) Review additional attributes generated from a systematic literature review, (4) Select and rank individually the 7 most important characteristics from the list and (5) Report their acceptability and stated preference ranking between the three treatment options.
Twenty women and 7 men with a mean age of 65 (range 51-85 years) participated in the focus groups. Twenty-four treatment characteristics were identified through focus groups and literature review. Efficacy, safety, out-of-pocket costs, strength of evidence and the option to self-administer were ranked as the most important attributes. The majority of patients stated preference for a daily sMTS if prescribed by their doctor.
This study revealed that efficacy, safety, costs, and convenience are important attributes of osteoporosis treatment for US patients at high risk for fractures when choosing between anabolic therapies, with a high stated preference for sMTS.
纳入三个焦点小组的美国骨质疏松症患者确定了疗效、安全性、成本和便利性，当在选择高偏好固体微结构透皮系统的合成代谢疗法时，这些都是治疗的重要属性。
本研究评估了患有骨质疏松症的美国患者在选择在家中每天自我管理abaloparatide-固体微结构透皮系统（sMTS）与其他合成代谢药物（即在家中每天皮下自我注射和每月在医生办公室进行皮下注射）时，对治疗属性的患者观点和相对重要性。
本研究包括系统文献综述、专家咨询和三个在线患者焦点小组（n=27），包括年龄在 50 岁以上、骨折风险高的患者。采用名义群体技术，要求患者：（1）单独确定在选择合成代谢治疗时对他们很重要的特征；（2）与其他患者分享想法和讨论观点；（3）从系统文献综述中生成额外属性；（4）从列表中单独选择并排名前 7 个最重要的特征；（5）报告他们对三种治疗方案的可接受性和既定偏好排名。
20 名女性和 7 名男性，平均年龄为 65 岁（范围 51-85 岁），参加了焦点小组。通过焦点小组和文献回顾确定了 24 种治疗特征。疗效、安全性、自付费用、证据强度和自我管理的选择被评为最重要的属性。如果医生开处方，大多数患者对每天使用 sMTS 的首选。
这项研究表明，对于骨折风险高的美国骨质疏松症患者，在选择合成代谢疗法时，疗效、安全性、成本和便利性是治疗的重要属性，对 sMTS 的高偏好。
